The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated Immunotherapies.
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
20
05
2020
revised:
09
11
2020
accepted:
16
12
2020
pubmed:
29
12
2020
medline:
3
11
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
Immune-checkpoint inhibitors and adoptive tumor-infiltrating lymphocyte (TIL) therapies have profoundly improved the survival of patients with melanoma. However, a majority of patients do not respond to these agents, and many responders experience disease relapse. Although numerous innovative treatments are being explored to offset the limitations of these agents, novel therapeutic combinations with immunotherapies have the potential to improve patient responses. In this study, we evaluated the antimelanoma activity of immunotherapy combinations with Telaglenastat (CB-839), a potent glutaminase inhibitor (GLSi) that has favorable systemic tolerance. In
Identifiants
pubmed: 33361272
pii: 1535-7163.MCT-20-0430
doi: 10.1158/1535-7163.MCT-20-0430
pmc: PMC7933078
mid: NIHMS1657413
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Glutaminase
EC 3.5.1.2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
500-511Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NIH HHS
ID : S10 OD012304
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA235510
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
PLoS One. 2013;8(4):e60031
pubmed: 23560068
Cell Metab. 2018 May 01;27(5):977-987.e4
pubmed: 29628419
J Clin Invest. 2020 Jul 1;130(7):3865-3884
pubmed: 32324593
Cancer Res. 2010 Nov 1;70(21):8736-47
pubmed: 20959481
JCI Insight. 2019 May 16;4(10):
pubmed: 31092734
Clin Cancer Res. 2013 Jan 15;19(2):393-403
pubmed: 23204132
J Med Chem. 2012 Dec 13;55(23):10551-63
pubmed: 23151085
Science. 2019 Nov 22;366(6468):1013-1021
pubmed: 31699883
Nat Med. 2019 Jan;25(1):141-151
pubmed: 30420753
J Transl Med. 2015 Jul 03;13:210
pubmed: 26139106
Cancer Discov. 2016 Feb;6(2):202-16
pubmed: 26645196
Biochem J. 2016 Mar 15;473(6):703-15
pubmed: 26699902
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
Mol Cancer Ther. 2014 Apr;13(4):890-901
pubmed: 24523301
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Oncogene. 2017 Jan 12;36(2):147-157
pubmed: 27270434
Clin Cancer Res. 2019 Nov 1;25(21):6429-6442
pubmed: 31439581
Cell. 2018 Dec 13;175(7):1780-1795.e19
pubmed: 30392958
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Mol Oncol. 2016 Jan;10(1):73-84
pubmed: 26365896
J Immunol Methods. 2005 Sep;304(1-2):43-59
pubmed: 16076473
Cancer Res. 2014 Dec 1;74(23):7037-47
pubmed: 25297634
J Clin Invest. 2016 May 2;126(5):1834-56
pubmed: 27043285
Pigment Cell Melanoma Res. 2017 Jul;30(4):428-435
pubmed: 28379630
Cancer Cell. 2013 Mar 18;23(3):302-15
pubmed: 23477830
Nat Rev Clin Oncol. 2019 Jun;16(6):356-371
pubmed: 30705439
Front Immunol. 2017 Feb 23;8:194
pubmed: 28280496
J Exp Med. 1998 Jul 20;188(2):277-86
pubmed: 9670040
Cancer Treat Rep. 1979 Jun;63(6):1033-8
pubmed: 380801
Immunol Rev. 2012 Sep;249(1):14-26
pubmed: 22889212
Clin Cancer Res. 2009 Dec 15;15(24):7538-7546
pubmed: 19996208
Pigment Cell Melanoma Res. 2012 Nov;25(6):732-9
pubmed: 22846158
Eur J Med Chem. 2019 Feb 1;163:215-242
pubmed: 30522056
J Immunol. 2010 Jul 15;185(2):1037-44
pubmed: 20554958
J Natl Cancer Inst. 2018 Jul 1;110(7):777-786
pubmed: 29267866